Anti-inflammatory Drugs Market Poised to Reach US$ 198.92 Billion by 2031, Growing at 8.7% CAGR on Rising Chronic Inflammatory Disorders | DataM Intelligence

According to DataM Intelligence, the Global Anti-inflammatory Drugs Market reached US$ 102.72 billion in 2023 and is expected to reach US$ 198.92 billion by 2031, growing at a CAGR of 8.7% during the forecast period 2024-2031. Market growth is driven by the rising prevalence of chronic inflammatory and autoimmune diseases, increasing adoption of biologics and targeted therapies, and expanding access to advanced treatments across hospital and retail pharmacy channels.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/anti-inflammatory-drugs-market?jd

North America Key Industry Developments
✅ November 2025: U.S.-based pharmaceutical companies intensified commercialization of biologic therapies for arthritis and inflammatory bowel disease, supported by favorable reimbursement frameworks.
✅ October 2025: Healthcare providers increased adoption of combination therapy regimens for chronic inflammatory conditions to improve long-term patient outcomes.
✅ September 2025: Expansion of specialty pharmacy networks enhanced patient access to injectable and biologic anti-inflammatory treatments.

Asia-Pacific Key Industry Developments
✅ November 2025: Growing investments in biologics manufacturing and biosimilar development across China and India supported regional market expansion.
✅ October 2025: Increased awareness programs for asthma, arthritis, and COPD boosted prescription volumes of oral and inhaled anti-inflammatory drugs.
✅ September 2025: Regional regulatory agencies streamlined approval pathways for anti-inflammatory generics and biosimilars, accelerating market penetration.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=anti-inflammatory-drugs-market
(Purchase 2 or more Reports and get 50% Discount)

Market Segmentation Analysis
-By Drug Class: Biologics and NSAIDs Drive Market Demand
Anti-inflammatory biologics represent a high-growth segment due to superior efficacy in autoimmune diseases. NSAIDs continue to dominate volume demand, while corticosteroids remain widely used for acute inflammation management.
-By Application: Arthritis and IBD Lead Utilization
Arthritis holds the largest application share, followed by inflammatory bowel disease, asthma, COPD, and multiple sclerosis, reflecting the rising burden of chronic inflammatory disorders.
-By Route of Administration: Oral Remains Dominant, Injectables Grow Fast
Oral formulations account for the largest share due to ease of administration, while injectable biologics represent the fastest-growing segment.
-By Distribution Channel: Hospital and Retail Pharmacies Lead
Hospital pharmacies dominate biologic dispensing, while retail and online pharmacies are expanding rapidly for oral and chronic-use therapies.

Regional Insights
North America dominates the Anti-inflammatory Drugs Market, supported by strong clinical research activity, early adoption of biologics, and favorable reimbursement policies. Asia-Pacific is the fastest-growing region, driven by expanding patient populations, improving healthcare infrastructure, and increasing availability of biosimilars. Europe maintains steady growth supported by universal healthcare coverage and rising biologic uptake.

Growth Drivers:
1. Rising Prevalence of Chronic Inflammatory and Autoimmune Diseases
2. Increasing Adoption of Biologic and Targeted Therapies
3. Expansion of Biosimilars Improving Treatment Affordability
4. Growing Geriatric Population Susceptible to Inflammatory Conditions
5. Advancements in Drug Delivery and Immune Modulation Technologies

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/anti-inflammatory-drugs-market?jd

Key Players:
The major global players in the Anti-inflammatory Drugs Market include AbbVie Inc., Johnson & Johnson Services, Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd, AstraZeneca, Novartis AG, Amgen Inc., GSK plc, Merck & Co., Inc., Bristol-Myers Squibb Company, and Viatris Inc., among others.

Emerging Players:
Emerging players shaping future innovation include UCB S.A., Rapport Therapeutics, and Apogee Therapeutics, Inc., focused on next-generation immune-selective and biologic anti-inflammatory therapies.

Key Highlights (Top 5 Key Players):
1. AbbVie Inc. leads the market with blockbuster biologics for autoimmune and inflammatory diseases.
2. Johnson & Johnson Services, Inc. maintains strong presence through diversified immunology and inflammation portfolios.
3. Pfizer Inc. focuses on both branded and biosimilar anti-inflammatory therapies.
4. Novartis AG drives innovation in immune-modulating and biologic treatments.
5. Amgen Inc. leverages advanced biologics and biosimilar expertise to expand global reach.

Unlock 360° Market Intelligence with DataM Intelligence Subscription Services:
https://www.datamintelligence.com/reports-subscription?jd

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape Analysis
✅ Company Profile Analysis
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updates
✅ Live Market & Pricing Trends
✅ Regulatory and Supply-Chain Analysis
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.